What smart money is saying about Lifecore Biomedical, Inc.
7 funds in our archive have pitched Lifecore Biomedical, Inc. — most recently Laughing Water Capital in December 2025.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Fund coverage · 7 theses
- Laughing Water CapitalDecember 2025
Lifecore Biomedical is a capacity-constrained CDMO with a 40-year quality record, sticky high-margin business, capable management, and visible upside with downside protection.
Read the full thesis - Laughing Water CapitalSeptember 2025
Lifecore Biomedical Inc (LFCR) is positioned to benefit from excess capacity in a high-demand CDMO market, supported by new customer wins and favorable regulatory developments, despite a recent stock decline due to misinterpretations of an S-3 filing.
Read the full thesis - Greenhaven Road CapitalSeptember 2025
LifeCore (LFCR) is a company whose promising developments and potential revenue growth are overshadowed by a misguided negative market reaction to a recent shelf offering filing.
Read the full thesis - Laughing Water CapitalJune 2025
Lifecore Biomedical Inc. is positioned for growth due to increasing demand for domestic biotech manufacturing and potential acquisition, suggesting a share price of over $13 today, with potential to reach closer to $16 by 2026.
Read the full thesis - Greenhaven Road CapitalJune 2025
LifeCore is a promising investment due to its significant manufacturing capacity, potential benefits from looming 200% tariffs on imported drugs, and conservative EBITDA growth projections that may prove to be underestimated.
Read the full thesis - Laughing Water CapitalDecember 2024
Lifecore Biomedical (LFCR) is experiencing a turnaround under new management, with plans for significant revenue growth and potential change of control by 2028, suggesting more than 100% upside in the future.
Read the full thesis - Greenhaven Road CapitalDecember 2024
Lifecore (LFCR) is poised for significant growth with the potential to triple production without additional capital, driven by contractual increases from its largest customer and enhanced margins under new leadership.
Read the full thesis
Read every full thesis on Lifecore Biomedical, Inc.
Unlock all 7 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→